Edition:
United States

Supernus Pharmaceuticals Inc (SUPN.OQ)

SUPN.OQ on NASDAQ Stock Exchange Global Market

22.45USD
7 Dec 2016
Change (% chg)

$-0.50 (-2.18%)
Prev Close
$22.95
Open
$22.50
Day's High
$22.70
Day's Low
$21.85
Volume
186,205
Avg. Vol
217,537
52-wk High
$26.82
52-wk Low
$9.52

SUPN.OQ

Chart for SUPN.OQ

About

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi... (more)

Overall

Beta: 1.87
Market Cap(Mil.): $1,136.22
Shares Outstanding(Mil.): 49.51
Dividend: --
Yield (%): --

Financials

  SUPN.OQ Industry Sector
P/E (TTM): 45.00 30.14 30.77
EPS (TTM): 0.51 -- --
ROI: 19.27 15.85 15.23
ROE: 21.45 16.96 16.56

BRIEF-Supernus provides business update

* Supernus Pharmaceuticals Inc - net product sales for Q3 of 2016 were $55.6 million, a 44.1% increase over $38.6 million in same period last year

Nov 14 2016

BRIEF-Supernus Pharmaceuticals sees 2016 net product sales in range of $205 mln to $210 mln

* Sees 2016 net product sales in range of $205 million to $210 million

Nov 14 2016

BRIEF-Supernus Pharmaceuticals files for non-timely 10-Q

* Additional time needed to solve issue concerning accounting treatment of $30 million royalty monetization deal recorded as revenue in July 2014

Nov 10 2016

BRIEF-Supernus Pharmaceuticals reports positive results from Phase IIB clinical trial for SPN-812

* Supernus announces positive results from Phase IIB clinical trial for SPN-812 in children with ADHD

Oct 11 2016

BRIEF-Supernus Pharma receives FDA tentative approval for expanded label of Trokendi XR

* Supernus receives FDA tentative approval for expanded label of Trokendi XR to include migraine prophylaxis in adults

Aug 19 2016

BRIEF-Supernus Pharma says Charles W Newhall III elected chairman

* Supernus announces resignation of Dr. James Barrett from board of directors; Charles W. Newhall, III elected chairman Source text for Eikon: Further company coverage:

Aug 12 2016

BRIEF-Supernus Pharmaceuticals CEO Jack Khattar joins scPharmaceuticals board

* Supernus Pharmaceuticals founder and CEO Jack Khattar joins scPharmaceuticals board of directors Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jul 12 2016

BRIEF-Supernus reiterates guidance

* Remains in discussions with FDA regarding its supplemental new drug application, or SNDA, for migraine

Jun 16 2016

Competitors

Earnings vs. Estimates